Cargando…
Étude interventionnelle sur le dolutégravir et les autres antirétroviraux dans l’athérosclérosclérose infra-clinique en milieu hospitalier de Kinshasa
INTRODUCTION: After 2016, the World Health Organization (WHO) proposed Dolutegravir (DTG) as an alternative first-line treatment for adults. Thus, the purpose of this study was to identify biomarkers of cardiometabolic risk capable of demonstrating the beneficial effect of Dolutegravir (DTG) compare...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The African Field Epidemiology Network
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460102/ https://www.ncbi.nlm.nih.gov/pubmed/37637394 http://dx.doi.org/10.11604/pamj.2023.45.63.39461 |
_version_ | 1785097570406629376 |
---|---|
author | Mashi, Murielle Longokolo Mambimbi, Marcel Mbula Situakibanza, Hippolyte Nani-Tuma Ndona, Madone Mandina Risassi, Jean-Robert Makulo Ngongo, Nadine Mayasi Bepouka, Ben Ossam, Odio Tshibola, Jean Mukaya Tshienda, Frédéric Tshibasu Kasongo, Eric Mukenge Nzita, Mamy Ngole Tuna, Lukiana Lulebo, Aimée Sonzi, Donatien Mangala Lusunsi, Christian Kisoka Longo-Mbenza, Benjamin |
author_facet | Mashi, Murielle Longokolo Mambimbi, Marcel Mbula Situakibanza, Hippolyte Nani-Tuma Ndona, Madone Mandina Risassi, Jean-Robert Makulo Ngongo, Nadine Mayasi Bepouka, Ben Ossam, Odio Tshibola, Jean Mukaya Tshienda, Frédéric Tshibasu Kasongo, Eric Mukenge Nzita, Mamy Ngole Tuna, Lukiana Lulebo, Aimée Sonzi, Donatien Mangala Lusunsi, Christian Kisoka Longo-Mbenza, Benjamin |
author_sort | Mashi, Murielle Longokolo |
collection | PubMed |
description | INTRODUCTION: After 2016, the World Health Organization (WHO) proposed Dolutegravir (DTG) as an alternative first-line treatment for adults. Thus, the purpose of this study was to identify biomarkers of cardiometabolic risk capable of demonstrating the beneficial effect of Dolutegravir (DTG) compared to other antiretrovirals in predicting atherosclerosis in people living with HIV (PLHIV) and hospitalized in Kinshasa Hospital. METHODS: we conducted an interventional study of people living with HIV who had received antiretroviral therapy (ART) for at least 6 months and were treated in the structures of the network coordinated by the Catholic Church (BDOM-Bureau Diocésain des Oeuvres Médicales) and of the University Clinics of Kinshasa (CUK) between January 2017 and December 2021. Subclinical atherosclerosis was defined as Pulsed Pressure (PP) ≥60 mm Hg; Carotid Intima-Media Thickness (CIMT) > 0.8 mm; and Systolic Pressure Index (SPI) < 0.9. Logistic regression was used in the statistical analysis of associations. RESULTS: a total of 334 PLHIV were recruited, of whom 96.1% (n=321) were on ART and 13.9% (n=13) were ART naïve patients. The mean age of PLHIV was 51±12 years with a female predominance (70.4%; n=235); the independent determinants of subclinical atherosclerosis were marital status (aOR: 4. 95% CI 1.5-10.5; p<0.006), low socioeconomic level (aOR: 10.7, 95% CI 2.3-48.7 p<0.002), duration of HIV infection (aOR: 6.6, 95% CI 2.8-16; p<0.0001), duration of antiretroviral therapy ≥9 years (aOR: 0.3, 95% CI 0.2-0.7; p<0.005) and total cholesterol ratio/high-density lipoprotein-cholesterol (CT/HDL-c)(aOR: 2, 95% CI 1.1-3.6; p= 0.034). The mean values of traditional and emergent variables were significantly higher in the previous ART regimen without DTG than in the new regimen with DTG. However, dyslipidemia was detected during the new DTG-based regimen. CONCLUSION: dyslipidemia was common during the DTG-based regimen. Marital status, low socioeconomic level, duration of HIV infection, duration of antiretroviral treatment beyond 9 years and the TC/HDL-c ratio were identified as determinants of subclinical atherosclerosis in PLHIV on ART hospitalized in the Kinshasa hospital. |
format | Online Article Text |
id | pubmed-10460102 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | The African Field Epidemiology Network |
record_format | MEDLINE/PubMed |
spelling | pubmed-104601022023-08-27 Étude interventionnelle sur le dolutégravir et les autres antirétroviraux dans l’athérosclérosclérose infra-clinique en milieu hospitalier de Kinshasa Mashi, Murielle Longokolo Mambimbi, Marcel Mbula Situakibanza, Hippolyte Nani-Tuma Ndona, Madone Mandina Risassi, Jean-Robert Makulo Ngongo, Nadine Mayasi Bepouka, Ben Ossam, Odio Tshibola, Jean Mukaya Tshienda, Frédéric Tshibasu Kasongo, Eric Mukenge Nzita, Mamy Ngole Tuna, Lukiana Lulebo, Aimée Sonzi, Donatien Mangala Lusunsi, Christian Kisoka Longo-Mbenza, Benjamin Pan Afr Med J Research INTRODUCTION: After 2016, the World Health Organization (WHO) proposed Dolutegravir (DTG) as an alternative first-line treatment for adults. Thus, the purpose of this study was to identify biomarkers of cardiometabolic risk capable of demonstrating the beneficial effect of Dolutegravir (DTG) compared to other antiretrovirals in predicting atherosclerosis in people living with HIV (PLHIV) and hospitalized in Kinshasa Hospital. METHODS: we conducted an interventional study of people living with HIV who had received antiretroviral therapy (ART) for at least 6 months and were treated in the structures of the network coordinated by the Catholic Church (BDOM-Bureau Diocésain des Oeuvres Médicales) and of the University Clinics of Kinshasa (CUK) between January 2017 and December 2021. Subclinical atherosclerosis was defined as Pulsed Pressure (PP) ≥60 mm Hg; Carotid Intima-Media Thickness (CIMT) > 0.8 mm; and Systolic Pressure Index (SPI) < 0.9. Logistic regression was used in the statistical analysis of associations. RESULTS: a total of 334 PLHIV were recruited, of whom 96.1% (n=321) were on ART and 13.9% (n=13) were ART naïve patients. The mean age of PLHIV was 51±12 years with a female predominance (70.4%; n=235); the independent determinants of subclinical atherosclerosis were marital status (aOR: 4. 95% CI 1.5-10.5; p<0.006), low socioeconomic level (aOR: 10.7, 95% CI 2.3-48.7 p<0.002), duration of HIV infection (aOR: 6.6, 95% CI 2.8-16; p<0.0001), duration of antiretroviral therapy ≥9 years (aOR: 0.3, 95% CI 0.2-0.7; p<0.005) and total cholesterol ratio/high-density lipoprotein-cholesterol (CT/HDL-c)(aOR: 2, 95% CI 1.1-3.6; p= 0.034). The mean values of traditional and emergent variables were significantly higher in the previous ART regimen without DTG than in the new regimen with DTG. However, dyslipidemia was detected during the new DTG-based regimen. CONCLUSION: dyslipidemia was common during the DTG-based regimen. Marital status, low socioeconomic level, duration of HIV infection, duration of antiretroviral treatment beyond 9 years and the TC/HDL-c ratio were identified as determinants of subclinical atherosclerosis in PLHIV on ART hospitalized in the Kinshasa hospital. The African Field Epidemiology Network 2023-05-26 /pmc/articles/PMC10460102/ /pubmed/37637394 http://dx.doi.org/10.11604/pamj.2023.45.63.39461 Text en Copyright: Murielle Longokolo Mashi et al. https://creativecommons.org/licenses/by/4.0/The Pan African Medical Journal (ISSN: 1937-8688). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Mashi, Murielle Longokolo Mambimbi, Marcel Mbula Situakibanza, Hippolyte Nani-Tuma Ndona, Madone Mandina Risassi, Jean-Robert Makulo Ngongo, Nadine Mayasi Bepouka, Ben Ossam, Odio Tshibola, Jean Mukaya Tshienda, Frédéric Tshibasu Kasongo, Eric Mukenge Nzita, Mamy Ngole Tuna, Lukiana Lulebo, Aimée Sonzi, Donatien Mangala Lusunsi, Christian Kisoka Longo-Mbenza, Benjamin Étude interventionnelle sur le dolutégravir et les autres antirétroviraux dans l’athérosclérosclérose infra-clinique en milieu hospitalier de Kinshasa |
title | Étude interventionnelle sur le dolutégravir et les autres antirétroviraux dans l’athérosclérosclérose infra-clinique en milieu hospitalier de Kinshasa |
title_full | Étude interventionnelle sur le dolutégravir et les autres antirétroviraux dans l’athérosclérosclérose infra-clinique en milieu hospitalier de Kinshasa |
title_fullStr | Étude interventionnelle sur le dolutégravir et les autres antirétroviraux dans l’athérosclérosclérose infra-clinique en milieu hospitalier de Kinshasa |
title_full_unstemmed | Étude interventionnelle sur le dolutégravir et les autres antirétroviraux dans l’athérosclérosclérose infra-clinique en milieu hospitalier de Kinshasa |
title_short | Étude interventionnelle sur le dolutégravir et les autres antirétroviraux dans l’athérosclérosclérose infra-clinique en milieu hospitalier de Kinshasa |
title_sort | étude interventionnelle sur le dolutégravir et les autres antirétroviraux dans l’athérosclérosclérose infra-clinique en milieu hospitalier de kinshasa |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460102/ https://www.ncbi.nlm.nih.gov/pubmed/37637394 http://dx.doi.org/10.11604/pamj.2023.45.63.39461 |
work_keys_str_mv | AT mashimuriellelongokolo etudeinterventionnellesurledolutegraviretlesautresantiretrovirauxdanslatheroscleroscleroseinfracliniqueenmilieuhospitalierdekinshasa AT mambimbimarcelmbula etudeinterventionnellesurledolutegraviretlesautresantiretrovirauxdanslatheroscleroscleroseinfracliniqueenmilieuhospitalierdekinshasa AT situakibanzahippolytenanituma etudeinterventionnellesurledolutegraviretlesautresantiretrovirauxdanslatheroscleroscleroseinfracliniqueenmilieuhospitalierdekinshasa AT ndonamadonemandina etudeinterventionnellesurledolutegraviretlesautresantiretrovirauxdanslatheroscleroscleroseinfracliniqueenmilieuhospitalierdekinshasa AT risassijeanrobertmakulo etudeinterventionnellesurledolutegraviretlesautresantiretrovirauxdanslatheroscleroscleroseinfracliniqueenmilieuhospitalierdekinshasa AT ngongonadinemayasi etudeinterventionnellesurledolutegraviretlesautresantiretrovirauxdanslatheroscleroscleroseinfracliniqueenmilieuhospitalierdekinshasa AT bepoukaben etudeinterventionnellesurledolutegraviretlesautresantiretrovirauxdanslatheroscleroscleroseinfracliniqueenmilieuhospitalierdekinshasa AT ossamodio etudeinterventionnellesurledolutegraviretlesautresantiretrovirauxdanslatheroscleroscleroseinfracliniqueenmilieuhospitalierdekinshasa AT tshibolajeanmukaya etudeinterventionnellesurledolutegraviretlesautresantiretrovirauxdanslatheroscleroscleroseinfracliniqueenmilieuhospitalierdekinshasa AT tshiendafrederictshibasu etudeinterventionnellesurledolutegraviretlesautresantiretrovirauxdanslatheroscleroscleroseinfracliniqueenmilieuhospitalierdekinshasa AT kasongoericmukenge etudeinterventionnellesurledolutegraviretlesautresantiretrovirauxdanslatheroscleroscleroseinfracliniqueenmilieuhospitalierdekinshasa AT nzitamamyngole etudeinterventionnellesurledolutegraviretlesautresantiretrovirauxdanslatheroscleroscleroseinfracliniqueenmilieuhospitalierdekinshasa AT tunalukiana etudeinterventionnellesurledolutegraviretlesautresantiretrovirauxdanslatheroscleroscleroseinfracliniqueenmilieuhospitalierdekinshasa AT luleboaimee etudeinterventionnellesurledolutegraviretlesautresantiretrovirauxdanslatheroscleroscleroseinfracliniqueenmilieuhospitalierdekinshasa AT sonzidonatienmangala etudeinterventionnellesurledolutegraviretlesautresantiretrovirauxdanslatheroscleroscleroseinfracliniqueenmilieuhospitalierdekinshasa AT lusunsichristiankisoka etudeinterventionnellesurledolutegraviretlesautresantiretrovirauxdanslatheroscleroscleroseinfracliniqueenmilieuhospitalierdekinshasa AT longombenzabenjamin etudeinterventionnellesurledolutegraviretlesautresantiretrovirauxdanslatheroscleroscleroseinfracliniqueenmilieuhospitalierdekinshasa |